Overview

Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema.

Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
The study aims to compare the effect of intravitreal non steroidal anti inflammatory (Diclofenac) versus the standard treatment of diabetic macular edema, intravitreal anti vascular endothelial growth factor (Ranibizumab), measuring central macular thickness changes and best corrected visual acuity.
Phase:
Phase 4
Details
Lead Sponsor:
Cairo University
Treatments:
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Diclofenac
Endothelial Growth Factors
Ranibizumab